Exact Mass: 1201.4748062

Exact Mass Matches: 1201.4748062

Found 11 metabolites which its exact mass value is equals to given mass value 1201.4748062, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

cobalt;[(2R,3S,4R,5S)-4,5-dihydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] hydrogen phosphate

cobalt;[(2R,3S,4R,5S)-4,5-dihydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] hydrogen phosphate

C53H81CoN11O15P- (1201.4982926)


   

(15Z,18Z,21Z,24Z,27Z)-3-oxotriacontapentaenoyl-CoA(4-)

(15Z,18Z,21Z,24Z,27Z)-3-oxotriacontapentaenoyl-CoA(4-)

C51H78N7O18P3S-4 (1201.4336678)


   

(3R,12Z,15Z,18Z,21Z,24Z,27Z)-3-hydroxytriacontahexaenoyl-CoA(4-)

(3R,12Z,15Z,18Z,21Z,24Z,27Z)-3-hydroxytriacontahexaenoyl-CoA(4-)

C51H78N7O18P3S-4 (1201.4336678)


   

(3R,12Z,15Z,18Z,21Z,24Z,27Z)-3-hydroxytriacontahexaenoyl-CoA(4-)

(3R,12Z,15Z,18Z,21Z,24Z,27Z)-3-hydroxytriacontahexaenoyl-CoA(4-)

C51H78N7O18P3S (1201.4336678)


A 3-hydroxy fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (3R,12Z,15Z,18Z,21Z,24Z,27Z)-3-hydroxytriacontahexaenoyl-CoA; major species at pH 7.3.

   

(15Z,18Z,21Z,24Z,27Z)-3-oxotriacontapentaenoyl-CoA(4-)

(15Z,18Z,21Z,24Z,27Z)-3-oxotriacontapentaenoyl-CoA(4-)

C51H78N7O18P3S (1201.4336678)


A 3-oxo-fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (15Z,18Z,21Z,24Z,27Z)-3-oxotriacontapentaenoyl-CoA.

   

CTAP (TFA)

CTAP (TFA)

C53H70F3N13O12S2 (1201.4660176000002)


CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction[1][2].

   

[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-3-{[(2r,3r,4s,5s,6r)-5-{[(1s,4r,5r,6s)-5,6-dihydroxy-3-(hydroxymethyl)-4-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohex-2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]methyl butanoate

[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-6-{[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-3-{[(2r,3r,4s,5s,6r)-5-{[(1s,4r,5r,6s)-5,6-dihydroxy-3-(hydroxymethyl)-4-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohex-2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]methyl butanoate

C47H79NO34 (1201.4483274)


   

{6-[(6-{[4,5-dihydroxy-2-(hydroxymethyl)-6-{[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl)oxy]-3-[(5-{[5,6-dihydroxy-3-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohex-2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl}methyl butanoate

{6-[(6-{[4,5-dihydroxy-2-(hydroxymethyl)-6-{[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl)oxy]-3-[(5-{[5,6-dihydroxy-3-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}cyclohex-2-en-1-yl]amino}-3,4-dihydroxy-6-methyloxan-2-yl)oxy]-4,5-dihydroxyoxan-2-yl}methyl butanoate

C47H79NO34 (1201.4483274)


   

n'-[(1s)-1-[(1-{4-[({[(1s)-1-{[(1r)-2-carbamoyl-1-{[(1s)-1-[({[(1r)-1-[({[(3s)-1-hydroxy-2-oxopiperidin-3-yl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]ethyl]-c-hydroxycarbonimidoyl}ethyl](hydroxy)carbamoyl}-2-hydroxyethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]-3,4,5,6-tetrahydropyrimidin-2-yl}-2-hydroxyethyl)-c-hydroxycarbonimidoyl]-8-hydroxy-9-oxo-1h,2h,3h,4h-pyrimido[1,2-a]quinolin-5-yl]-2-hydroxybutanediimidic acid

n'-[(1s)-1-[(1-{4-[({[(1s)-1-{[(1r)-2-carbamoyl-1-{[(1s)-1-[({[(1r)-1-[({[(3s)-1-hydroxy-2-oxopiperidin-3-yl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]ethyl]-c-hydroxycarbonimidoyl}ethyl](hydroxy)carbamoyl}-2-hydroxyethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]-3,4,5,6-tetrahydropyrimidin-2-yl}-2-hydroxyethyl)-c-hydroxycarbonimidoyl]-8-hydroxy-9-oxo-1h,2h,3h,4h-pyrimido[1,2-a]quinolin-5-yl]-2-hydroxybutanediimidic acid

C48H67N17O20 (1201.4748062)


   

n'-[1-({1-[4-({[(1-{[2-carbamoyl-1-({1-[({[1-({[(1-hydroxy-2-oxopiperidin-3-yl)-c-hydroxycarbonimidoyl]methyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)ethyl](hydroxy)carbamoyl}-2-hydroxyethyl)-c-hydroxycarbonimidoyl]methyl}-c-hydroxycarbonimidoyl)-3,4,5,6-tetrahydropyrimidin-2-yl]-2-hydroxyethyl}-c-hydroxycarbonimidoyl)-8-hydroxy-9-oxo-1h,2h,3h,4h-pyrimido[1,2-a]quinolin-5-yl]-2-hydroxybutanediimidic acid

n'-[1-({1-[4-({[(1-{[2-carbamoyl-1-({1-[({[1-({[(1-hydroxy-2-oxopiperidin-3-yl)-c-hydroxycarbonimidoyl]methyl}-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}methyl)-c-hydroxycarbonimidoyl]ethyl}-c-hydroxycarbonimidoyl)ethyl](hydroxy)carbamoyl}-2-hydroxyethyl)-c-hydroxycarbonimidoyl]methyl}-c-hydroxycarbonimidoyl)-3,4,5,6-tetrahydropyrimidin-2-yl]-2-hydroxyethyl}-c-hydroxycarbonimidoyl)-8-hydroxy-9-oxo-1h,2h,3h,4h-pyrimido[1,2-a]quinolin-5-yl]-2-hydroxybutanediimidic acid

C48H67N17O20 (1201.4748062)